UPDATE: Piper Jaffray Initiates Coverage on Incyte as 2014 Biotech Sector Outlook Remains Strong
November 27, 2013 at 11:16 AM EST
In a report published Wednesday, Piper Jaffray analyst Joshua E. Schimmer initiated coverage on Incyte Corporation (NASDAQ: INCY ) with an Overweight rating and $56.00 price target. In the report, Piper Jaffray noted, “We are initiating, resuming or assuming coverage on 16 biotechnology companies. We believe the outlook for the